PreDxion Bio's tech helps tailor treatments to patient's immune system

The team at PreDxion Bio isn't just trying to come up with new technology to help sick people. It's trying to help really really sick people. The University of Michigan’s Zell Lurie Institute for Entrepreneurial Studies spinoff is in the early stages of developing a diagnostic device to help create custom diagnosis. The technology is coming from U-M's Pediatric Critical Care Precision Laboratory.

"One of the main thrusts of our lab is to develop new diagnostic tools to treat these really sick patients," says Walker McHugh, co-founder of PreDxion Bio and a biomedical engineering graduate student at the University of Michigan. He is launching the startup with Dr. Timothy Cornell, a physician at U-M, and Caroline Landau, an MBA student at U-M's Ross School of Business.

PreDxion Bio's technology is a patent-pending diagnostic device that gives doctors the information they need to precisely tailor treatments to a specific patient's immune response. The idea is to make precision care more available to people in intensive care.

The team has created a prototype and is currently entering it into a variety of high-profile business plan competitions. It is one of two U-M startups to make it to the Rice Business Plan Competition next week where it will compete for $1 million in prizes.

The company plans to use any winnings from business plan competitions and any seed capital it can raise to develop a next generation version of its technology that will be manufacturing grade. It hopes to then submit it for clinical trials that will eventually lead to FDA approval in 3-5 years. In the meantime PreDxion Bio's team is looking for interested parties to help it get to the next step.

"We're talking with strategic partners," McHugh says.

Source: Walker McHugh and Caroline Landau, co-founders of PreDxion Bio
Writer: Jon Zemke

Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story? Sign up for free solutions-based reporting in your inbox each week.